President Trump was taken aback when Treasury chief Steven Mnuchin said the U.S. asked China's trade delegation to reschedule a farm tour.Politicsread more
As China marks the 70th anniversary of its founding on Oct. 1, CNBC takes a look at the rise of the Asian giant through the years — and projections of where it's headed.China Economyread more
Google does not have to apply the right to be forgotten globally, the European Court of Justice ruled Tuesday.Technologyread more
The highest court in the U.K. has determined that the government's decision to suspend parliament for five weeks was unlawful.Europe Politicsread more
Fiat will have to repay up to 30 million euros back in taxes, Europe's second highest court ruled Tuesday.Politicsread more
The tax cut came as Indian Prime Minister Narendra Modi's government attempts to spur the country's slowing economy.Asia Economyread more
Lawmakers in Congress on Monday pressed for full disclosure of a whistleblower's complaint about President Donald Trump as Democratic calls for impeachment intensified over...Politicsread more
Stocks have been grinding sideways, but technical analysts say once they breakout, the move to the upside could be powerful.Market Insiderread more
The brewer also issued an additional 189,354,000 shares. Budweiser APAC's IPO is now expected to raise about US$5 billion.China Marketsread more
Rising home prices and conservative borrowing have today's homeowners sitting on a record amount of potential cash. Today's mortgage holders saw their home equity increase by...Real Estateread more
Shareholders are accusing Tesla of improperly valuing the SolarCity deal, providing flawed analysis and misleading investors.Technologyread more
Sept 9 (Reuters) - Drug developer Neurotrope Inc's shares tumbled nearly 80% on Monday after the company said its experimental treatment for Alzheimer's disease did not meet the main goal of a mid-stage study.
This is the second time in just over two years that the treatment - Bryostatin-1 - failed to meet its targets, raising questions about the drug's future. (https://reut.rs/2kCiDyh)
The treatment, Bryostatin-1, did not show any significant difference in patients after 13 weeks compared with those on placebo, the company said on Monday.
Neurotrope said it intends to conduct a complete review of the data to determine next steps in the treatment's development.
Alzheimer's disease, which affects parts of the brain that control thought, memory and language, is a progressive condition that could seriously disrupt a patient's ability to carry out daily activities.
Several drugmakers such as Eli Lilly, AstraZeneca Plc, Roche AG, Pfizer Inc, Merck and Co Inc and Johnson and Johnson have all previously failed in their attempts to develop treatments for the memory-robbing disease.
The company's shares were trading down 77% at $1 in premarket trading. (Reporting by Manojna Maddipatla in Bengaluru Editing by Saumyadeb Chakrabarty)